Sign In
Last checked at 
11 Sep 2025 17:11
11 September 2025
Convatec Group Plc
("Convatec" or "the Company")
Director/ PDMR Shareholding
The Company has been notified of the following transactions in relation to Persons Discharging Managerial Responsibility ("PDMR") under the Convatec 2017 Save as You Earn share option scheme (the "SAYE Scheme") in respect of ordinary shares of 10 pence each in the Company ("Shares").
Grant of SAYE options
On 10 September 2025, options were granted to Jonny Mason, Interim Chief Executive Officer, and Fiona Ryder, Interim Chief Financial Officer, over a total of 18,6860 ordinary shares of 10 pence each in the Company ("Shares") at an option price of 196.46 pence per share under the SAYE Scheme. The options will be become exercisable in the ordinary course from 1 September 2028.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1
| Details of the person discharging managerial responsibilities / person closely associated | |||||
a)
| Name
| Jonny Mason | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Interim Chief Executive Officer and PDMR | ||||
b)
| Initial notification /Amendment
| Initial Notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a)
| Name
| Convatec Group Plc | ||||
b)
| LEI
| 213800LS272L4FIDOH92 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument | Ordinary share of 10p each in Convatec Group Plc | ||||
Identification code | GB00BD3VFW73 | |||||
b)
| Nature of the transaction | Grant of options under the Convatec Group PLC 2017 Save As You Earn Scheme | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | |||||
- Aggregated volume | N/A - single transaction | |||||
- Price | ||||||
e)
| Date of the transaction
| 10 September 2025 | ||||
f)
| Place of the transaction
| Outside a trading venue | ||||
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1
| Details of the person discharging managerial responsibilities / person closely associated | |||||
a)
| Name
| Fiona Ryder | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Interim Chief Financial Officer and PDMR | ||||
b)
| Initial notification /Amendment
| Initial Notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a)
| Name
| Convatec Group Plc | ||||
b)
| LEI
| 213800LS272L4FIDOH92 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument | Ordinary share of 10p each in Convatec Group Plc | ||||
Identification code | GB00BD3VFW73 | |||||
b)
| Nature of the transaction | Grant of options under the Convatec Group PLC 2017 Save As You Earn Scheme | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | |||||
- Aggregated volume | N/A - single transaction | |||||
- Price | ||||||
e)
| Date of the transaction
| 10 September 2025 | ||||
f)
| Place of the transaction
| Outside a trading venue | ||||
Enquiries
James Kerton Company Secretary
Tel: +44 (7827) 036059
Email: cosec@convatec.com
Convatec Group Plc's LEI code is 213800LS272L4FIDOH92
Classification: 2.2 Information disclosed under article 19 of the Market Abuse Regulation
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com
Follow the stocks
